FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783159512> ?p ?o ?g. }

• W2783159512 endingPage "15" @default.
• W2783159512 startingPage "9" @default.
• W2783159512 abstract "A phase II trial of pasireotide was performed to assess its efficacy and safety in advanced or metastatic hepatocellular carcinoma (HCC).Patients with advanced HCC and Child-Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days. Primary endpoint was disease control rate. Secondary endpoints were time to tumor progression, response rate, treatment-related adverse events, and overall survival. Serum insulin growth factor-1 was measured before and after pasireotide.Twenty patients were treated and evaluable. Eighteen patients (90%) had prior therapy; 16 patients (80%) had multiple therapies. Median age was 65, 75% had Barcelona Clinic Liver Cancer stage C, and 55% had metastatic disease. The main toxicity was hyperglycemia. Rare adverse effects included reversible grade 4 elevation in alanina transaminase/aspartate transaminase in one patient. The best response was stable disease in 9 patients (45%). Median time to tumor progression for the 20 patients was 3 months, and median survival was 9 months.Pasireotide had limited clinical benefit as second-line or third-line treatment in patients with advanced or metastatic HCC. Low baseline insulin growth factor-1 level may be indicative when SOM230 treatment may be ineffective, and decreasing levels after treatment may be indicative of disease control." @default.
• W2783159512 created "2018-01-26" @default.
• W2783159512 creator A5001610159 @default.
• W2783159512 creator A5037501297 @default.
• W2783159512 creator A5037593731 @default.
• W2783159512 creator A5038264812 @default.
• W2783159512 creator A5059946830 @default.
• W2783159512 creator A5065012486 @default.
• W2783159512 creator A5071339563 @default.
• W2783159512 date "2018-01-01" @default.
• W2783159512 modified "2023-10-16" @default.
• W2783159512 title "Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma" @default.
• W2783159512 cites W1512561726 @default.
• W2783159512 cites W1828082159 @default.
• W2783159512 cites W1971837077 @default.
• W2783159512 cites W1988464279 @default.
• W2783159512 cites W1996375200 @default.
• W2783159512 cites W2004865889 @default.
• W2783159512 cites W2011883791 @default.
• W2783159512 cites W2012408740 @default.
• W2783159512 cites W2017352677 @default.
• W2783159512 cites W2019008773 @default.
• W2783159512 cites W2023636724 @default.
• W2783159512 cites W2029378031 @default.
• W2783159512 cites W2031810225 @default.
• W2783159512 cites W2034154968 @default.
• W2783159512 cites W2046382053 @default.
• W2783159512 cites W2048179918 @default.
• W2783159512 cites W2048922160 @default.
• W2783159512 cites W2051684210 @default.
• W2783159512 cites W2052730188 @default.
• W2783159512 cites W2067084033 @default.
• W2783159512 cites W2071368773 @default.
• W2783159512 cites W2081720784 @default.
• W2783159512 cites W2093059993 @default.
• W2783159512 cites W2096482848 @default.
• W2783159512 cites W2120967735 @default.
• W2783159512 cites W2122718995 @default.
• W2783159512 cites W2128965737 @default.
• W2783159512 cites W2132711541 @default.
• W2783159512 cites W2140587309 @default.
• W2783159512 cites W2145386424 @default.
• W2783159512 cites W2155161822 @default.
• W2783159512 cites W2169298675 @default.
• W2783159512 cites W2399683143 @default.
• W2783159512 cites W2410810603 @default.
• W2783159512 cites W2414894582 @default.
• W2783159512 cites W2419015487 @default.
• W2783159512 cites W2560499218 @default.
• W2783159512 cites W348901093 @default.
• W2783159512 cites W4250058955 @default.
• W2783159512 doi "https://doi.org/10.2147/jhc.s153672" @default.
• W2783159512 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5769585" @default.
• W2783159512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29392123" @default.
• W2783159512 hasPublicationYear "2018" @default.
• W2783159512 type Work @default.
• W2783159512 sameAs 2783159512 @default.
• W2783159512 citedByCount "11" @default.
• W2783159512 countsByYear W27831595122019 @default.
• W2783159512 countsByYear W27831595122020 @default.
• W2783159512 countsByYear W27831595122021 @default.
• W2783159512 countsByYear W27831595122022 @default.
• W2783159512 crossrefType "journal-article" @default.
• W2783159512 hasAuthorship W2783159512A5001610159 @default.
• W2783159512 hasAuthorship W2783159512A5037501297 @default.
• W2783159512 hasAuthorship W2783159512A5037593731 @default.
• W2783159512 hasAuthorship W2783159512A5038264812 @default.
• W2783159512 hasAuthorship W2783159512A5059946830 @default.
• W2783159512 hasAuthorship W2783159512A5065012486 @default.
• W2783159512 hasAuthorship W2783159512A5071339563 @default.
• W2783159512 hasBestOaLocation W27831595121 @default.
• W2783159512 hasConcept C126322002 @default.
• W2783159512 hasConcept C141071460 @default.
• W2783159512 hasConcept C143998085 @default.
• W2783159512 hasConcept C197934379 @default.
• W2783159512 hasConcept C203092338 @default.
• W2783159512 hasConcept C2777433750 @default.
• W2783159512 hasConcept C2778019345 @default.
• W2783159512 hasConcept C2779371878 @default.
• W2783159512 hasConcept C2984496839 @default.
• W2783159512 hasConcept C31760486 @default.
• W2783159512 hasConcept C535046627 @default.
• W2783159512 hasConcept C71315377 @default.
• W2783159512 hasConcept C71924100 @default.
• W2783159512 hasConcept C90924648 @default.
• W2783159512 hasConceptScore W2783159512C126322002 @default.
• W2783159512 hasConceptScore W2783159512C141071460 @default.
• W2783159512 hasConceptScore W2783159512C143998085 @default.
• W2783159512 hasConceptScore W2783159512C197934379 @default.
• W2783159512 hasConceptScore W2783159512C203092338 @default.
• W2783159512 hasConceptScore W2783159512C2777433750 @default.
• W2783159512 hasConceptScore W2783159512C2778019345 @default.
• W2783159512 hasConceptScore W2783159512C2779371878 @default.
• W2783159512 hasConceptScore W2783159512C2984496839 @default.
• W2783159512 hasConceptScore W2783159512C31760486 @default.
• W2783159512 hasConceptScore W2783159512C535046627 @default.
• W2783159512 hasConceptScore W2783159512C71315377 @default.
• W2783159512 hasConceptScore W2783159512C71924100 @default.

• next